Drug Discovery Outsourcing Market

Drug Discovery Outsourcing Market (Workflow: Target Identification & Screening, Lead Identification & Candidate Optimization, Development of Disease Models, Pre-formulation Studies, Entire Clinical Trials, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Drug Discovery Outsourcing Market Outlook 2031

  • The global industry was valued at US$ 3.6 Bn in 2022
  • It is projected to advance at a CAGR of 7.8% from 2023 to 2031 and reach more than US$ 7.5 Bn by 2031

Analysts’ Viewpoint

Rise in R&D spending by pharmaceutical companies and increase in focus on development of personalized medicines and orphan drugs are driving the global market. Pharmaceutical and biotech companies require a range of services to support their drug development efforts. This is fueling the drug discovery outsourcing market demand. Increase in complexity of drug development and advancements in technology & automation offer lucrative market opportunities for market players.

The market includes a diverse range of service providers, including contract research organizations (CROs) and academic research organizations (AROs). Outsourcing can also help reduce drug development costs. New technologies such as AI, ML, and robotics are being used to improve the efficiency and accuracy of drug discovery activities, which is augmenting growth of the drug discovery outsourcing industry.

Drug Discovery Outsourcing Market

Global Drug Discovery Outsourcing Market Introduction

Drug discovery is a complex and time-consuming process that involves identification, development, and testing of new medications to treat various diseases. The process typically involves several stages, including target identification, lead discovery, lead optimization, preclinical testing, clinical trials, and regulatory approval.

Outsourcing involves hiring a third-party organization to perform some or all of the drug discovery process. It can also be used for clinical trials and regulatory approval, although these are typically more complex and may require more specialized expertise. Chemical and biology services are the primary types of drug discovery outsourcing.

Outsourcing allows pharmaceutical companies to eliminate the need to invest in expensive laboratory equipment and specialized personnel, thus reducing overhead costs. Outsourcing firms have a team of highly skilled scientists and researchers with expertise in different areas of drug discovery. Outsourcing can also help companies access new technologies and techniques that they may not have otherwise been able to afford or implement on their own. These advantages of drug discovery outsourcing fuel market development.

Increase in R&D Spending by Global Pharmaceutical Companies

The global pharmaceutical industry has experienced a significant rise in research and development (R&D) spending in the past few years, driven by surge in demand for innovative drugs to treat a range of diseases, increase in prevalence of chronic diseases such as cancer and diabetes, and emergence of new technologies such as gene therapy and immunotherapy. However, drug discovery is a complex and time-consuming process that requires significant investment in terms of time, money, and expertise.

Outsourcing enables pharmaceutical companies to focus on the commercialization of products, while outsourcing companies take care of the research and development process. These companies have a team of experts with knowledge of various therapeutic areas, which helps in accelerating the drug discovery process. Hence, pharmaceutical companies are investing significantly on R&D.

The drug discovery process is complex, and any errors or delays could result in significant costs and delays in bringing a drug to market. Outsourcing firms have the expertise and experience to manage the risks involved and help pharmaceutical companies mitigate potential losses. Outsourcing can help pharmaceutical companies reduce costs and accelerate the drug discovery process, allowing them to bring innovative drugs to market faster and more efficiently.

Growing Focus on Development of Personalized Medicines and Orphan Drugs

Pharmaceutical companies are focused on streamlining internal R&D systems, and hence are employing external resources for the development of newer drugs with higher success rates. These companies are focused on outsourcing both the discovery of new therapeutic agents and their thorough validation to drug discovery service providers, as these have become the key priorities of drug discovery research.

Companies have entered into collaborations with academia and drug discovery service providers for the integration of human genetics research in drug discovery & development programs. Moreover, genomics and proteomics find a range of applications in drug discovery, such as for safety biomarker development & application, target identification & validation, and novel antibody drug development.

Personalized medicine involves usage of patient-specific data to develop tailored therapies that are more effective and have fewer side effects. This requires deep understanding of the biology of disease and mechanisms underlying drug efficacy, which can be achieved through outsourcing drug discovery activities.

Adoption of orphan drugs has been increasing owing to rise in awareness about treatment options available for orphan diseases. Moreover, prevalence of orphan diseases has been increasing, creating a need to expand the production of orphan drugs. Drug manufacturers are focused on the development of therapies for orphan diseases. Eighteen orphan drugs were approved by the FDA in 2022.

Production of orphan drugs provides higher return on investment to manufacturers. Hence, pharmaceutical companies are focusing on the manufacturing of orphan drugs for rare diseases. Companies engaged in the marketing of orphan drugs generate high revenue, owing to high cost of orphan drugs. Development of phase-III orphan drugs costs over 50% of that of non-orphan drugs owing to various benefits offered such as fee waivers and tax credits.

Surge in Demand for Chemical Services

In terms of services, the chemical services segment accounted for the largest global drug discovery outsourcing market share in 2022. The segment is likely to lead the global market in the next few years.

Chemical services in drug discovery outsourcing refer to the synthesis of small molecules. This involves the design and synthesis of new compounds that can potentially be used as drugs and optimization of existing molecules to improve their efficacy and safety. Chemical services also include production of libraries of small molecules for high-throughput screening.

Small molecules are preferred over other types of drugs because they can be easily synthesized, are more stable, and have better pharmacokinetic properties. This has led to a growing need for chemical services in drug discovery outsourcing to support the development of small molecule drugs.

Increase in complexity of drug discovery is fueling demand for chemical services. Pharmaceutical and biotech companies are turning to outsourcing to access the expertise and resources they need as drug targets become more challenging and the drug development process becomes more intricate.

Chemical service providers are able to offer specialized knowledge and experience in the design and synthesis of small molecules, which can help accelerate the drug discovery process. Furthermore, the chemical services segment is benefiting from advancements in technology and automation.

Rise in Application of Drug Discovery Outsourcing in Oncology Sector

Based on therapeutic area, the oncology segment is likely to lead the global market during the forecast period. Increase in incidence of cancer across the globe is fueling demand for more effective treatments. Cancer is one of the leading causes of death globally, and the need for new and innovative therapies is critical.

Outsourcing drug discovery activities in oncology could provide several advantages to pharmaceutical and biotech companies. One of the primary benefits is access to a broader range of expertise and resources, which can help accelerate the drug discovery process and improve the likelihood of success. Outsourcing could also help reduce development costs and speed up time to market, which is essential in the highly competitive oncology market.

Drug discovery outsourcing providers specializing in oncology have a deep understanding of the complex biology of cancer and the mechanisms underlying tumor growth and progression. This expertise can be leveraged to develop more targeted and personalized therapies that are tailored to the unique needs of individual patients.

The oncology segment is benefiting from increasing availability of advanced technologies and platforms that can support drug discovery efforts.

Advantages in Drug Development Propelling Small Molecules Segment

In terms of drug type, the small molecules segment is projected to account for major share of the global drug discovery outsourcing market during the forecast period.

Small molecules are organic compounds with a low molecular weight that are the basis of most drugs. The primary advantage of small molecules is the ability to easily penetrate cell membranes, making them effective at targeting intracellular proteins and enzymes. This makes them a preferred option for many therapeutic areas, including oncology, infectious diseases, and neurological disorders.

Small molecules also have a long history of usage in drug development, with several approved drugs on the market being small molecules. Thus, knowledge and experience in the design and synthesis of small molecules could help accelerate the drug discovery process.

Small molecules are generally more stable than other types of drugs, such as biologics, making them easier to manufacture and store. This can help reduce development costs and improve the scalability of drug production.

Small molecules are amenable to high-throughput screening, which is a key step in the drug discovery process. Large libraries of small molecules can be rapidly screened for their potential to interact with specific targets, allowing researchers to identify promising leads for further optimization.

Regional Outlook

As per drug discovery outsourcing trends, North America accounted for major share of the global drug discovery outsourcing market in 2022. The region is anticipated to dominate the global industry during the forecast period, with the U.S. being the largest contributor to revenue growth.

Increase in incidence of cardiovascular and neurovascular diseases across is a key factor fueling the market in the region. Furthermore, strong presence of prominent players and their effective strategies are expected to drive market progress in the region.

Availability of advanced technologies and platforms also contributed to market growth in North America. The region is a hub for innovation in areas such as artificial intelligence, high-throughput screening, and genomics, which are critical to the drug discovery process.

The drug discovery outsourcing market size in Asia Pacific is projected to increase in the near future, owing to high disease prevalence, emergence of local companies, and presence of a large patient pool. Multiple strategic initiatives implemented by innovative companies are expected to bolster market expansion in the region.

Analysis of Key Players in Global Drug Discovery Outsourcing Industry

Leading players operating in the global market are Charles River Laboratories International, Inc., WuXi AppTec Co., Ltd., Albany Molecular Research, Inc., GVK Biosciences Private Limited, Sygnature Discovery, Pharmaron Beijing Co., Ltd., Domainex Ltd., Thermo Fisher Scientific, Inc., Jubilant Biosys Ltd., Evotec SE, Eurofins Discovery, and GenScript Biotech Corporation.

As per the drug discovery outsourcing market forecast, companies are engaged in merger & acquisition, strategic partnerships, and new product launches to expand industry presence. Key players are focusing on following the market trends to avail lucrative revenue opportunities.

Key Developments in Global Drug Discovery Outsourcing Market

  • In July 2020, Piramal Critical Care (PCC), a business division of Piramal Pharma Limited (PPL), announced strategic collaboration with Medivant Healthcare, a U.S.-based pharmaceutical outsourcing facility, in order to help address the notable shortage of injectable drugs in hospitals throughout the U.S.

The drug discovery outsourcing market report profiles the top players based on various parameters including company overview, financial summary, strategies, product portfolio, segments, and recent advancements.

Global Drug Discovery Outsourcing Market Snapshot

Attribute Detail

Size in 2022

US$ 3.6 Bn

Forecast (Value) in 2031

More than US$ 7.5 Bn

Growth Rate (CAGR)

7.8%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Type
    • Chemical Services
    • Biology Services
  • Drug Molecule
    • Small Molecules
    • Large Molecules
  • Discovery Approach
    • Empirical Drug Discovery
    • Rational Drug Discovery
  • Workflow
    • Target Identification and Screening
    • Lead Identification and Candidate Optimization
    • Development of Disease Models
    • Pre-formulation Studies
    • Entire Clinical Trials
    • Others
  • Therapeutic Area
    • Anti-infective
    • Cardiovascular
    • Central Nervous System
    • Dermatology
    • Endocrine
    • Gastrointestinal
    • Genitourinary System
    • Immunomodulation
    • Oncology
    • Ophthalmology
    • Respiratory System
    • Others
  • End-user
    • Pharmaceutical Companies
    • Biotechnology Companies
    • Academic Institutes

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Charles River Laboratories International, Inc.
  • WuXi AppTec Co., Ltd.
  • Albany Molecular Research Inc.
  • GVK Biosciences Private Limited
  • Sygnature Discovery
  • Pharmaron Beijing Co., Ltd.
  • Domainex Ltd.
  • Thermo Fisher Scientific, Inc.
  • Jubilant Biosys Ltd.
  • Evotec SE
  • Eurofins Discovery
  • GenScript Biotech Corporation

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global drug discovery outsourcing market in 2022?

It was valued at US$ 3.6 Bn in 2022

How big will be the drug discovery outsourcing industry in 2031?

It is projected to reach more than US$ 7.5 Bn in 2031

How is the drug discovery outsourcing business anticipated to grow during the forecast period?

It is likely to expand at a CAGR of 7.8% from 2023 to 2031

Which drug discovery outsourcing segment held major share in 2022?

The small molecules segment accounted for leading share in 2022

Which region is more lucrative for drug discovery outsourcing?

North America is expected to be a more lucrative region during the forecast period

Who are the prominent drug discovery outsourcing companies?

Charles River Laboratories International, Inc., WuXi AppTec Co., Ltd., Albany Molecular Research Inc., GVK Biosciences Private Limited, Sygnature Discovery, Pharmaron Beijing Co., Ltd., Domainex Ltd., Thermo Fisher Scientific, Inc., Jubilant Biosys Ltd., Evotec SE, Eurofins Discovery, and GenScript Biotech Corporation

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Drug Discovery Outsourcing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Drug Discovery Outsourcing Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Technological Advancements

        5.2. Overview: Integrated Drug Discovery (IDD) outsourcing

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Type, 2017-2031

            6.3.1. Chemistry Services

            6.3.2. Biology Services

        6.4. Market Attractiveness Analysis, by Type

    7. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Drug Molecule

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Drug Molecule, 2017-2031

            7.3.1. Small Molecules

            7.3.2. Large Molecules

        7.4. Market Attractiveness Analysis, by Drug Molecule

    8. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Discovery Approach

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Discovery Approach, 2017-2031

            8.3.1. Empirical Drug Discovery

            8.3.2. Rational Drug Discovery

        8.4. Market Attractiveness Analysis, by Discovery Approach

    9. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Therapeutic Area

        9.1. Introduction & Definition

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by Therapeutic Area, 2017-2031

            9.3.1. Anti-infective

            9.3.2. Cardiovascular

            9.3.3. Central Nervous System

            9.3.4. Dermatology

            9.3.5. Endocrine

            9.3.6. Gastrointestinal

            9.3.7. Genitourinary System

            9.3.8. Immunomodulation

            9.3.9. Oncology

            9.3.10. Ophthalmology

            9.3.11. Respiratory System

            9.3.12. Others

        9.4. Market Attractiveness Analysis, by Therapeutic Area

    10. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Workflow

        10.1. Introduction & Definition

        10.2. Key Findings/Developments

        10.3. Market Value Forecast, by Workflow, 2017-2031

            10.3.1. Target Identification and Screening

            10.3.2. Lead Identification and Candidate Optimization

            10.3.3. Development of Disease Models

            10.3.4. Pre-formulation Studies

            10.3.5. Entire Clinical Trials

            10.3.6. Others

        10.4. Market Attractiveness Analysis, by Workflow

    11. Global Drug Discovery Outsourcing Market Analysis and Forecast, by End-user

        11.1. Introduction & Definition

        11.2. Key Findings/Developments

        11.3. Market Value Forecast, by Discovery Approach, 2017-2031

            11.3.1. Pharmaceutical Companies

            11.3.2. Biotechnology Companies

            11.3.3. Academic Institutes

        11.4. Market Attractiveness Analysis, by End-user

    12. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Region

        12.1. Key Findings

        12.2. Market Value Forecast, by Region, 2017-2031

            12.2.1. North America

            12.2.2. Europe

            12.2.3. Asia Pacific

            12.2.4. Latin America

            12.2.5. Middle East & Africa

        12.3. Market Attractiveness Analysis, by Region

    13. North America Drug Discovery Outsourcing Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Type, 2017-2031

            13.2.1. Chemistry Services

            13.2.2. Biology Services

        13.3. Market Value Forecast, by Drug Molecule, 2017-2031

            13.3.1. Small Molecules

            13.3.2. Large Molecules

        13.4. Market Value Forecast, by Discovery Approach, 2017-2031

            13.4.1. Empirical Drug Discovery

            13.4.2. Rational Drug Discovery

        13.5. Market Value Forecast, by Therapeutic Area, 2017-2031

            13.5.1. Anti-infective

            13.5.2. Cardiovascular

            13.5.3. Central Nervous System

            13.5.4. Dermatology

            13.5.5. Endocrine

            13.5.6. Gastrointestinal

            13.5.7. Genitourinary System

            13.5.8. Immunomodulation

            13.5.9. Oncology

            13.5.10. Ophthalmology

            13.5.11. Respiratory System

            13.5.12. Others

        13.6. Market Value Forecast, by Workflow, 2017-2031

            13.6.1. Target Identification and Screening

            13.6.2. Lead Identification and Candidate Optimization

            13.6.3. Development of Disease Models

            13.6.4. Pre-formulation Studies

            13.6.5. Entire Clinical Trials

            13.6.6. Others

        13.7. Market Value Forecast, by End-user, 2017-2031

            13.7.1. Pharmaceutical Companies

            13.7.2. Biotechnology Companies

            13.7.3. Academic Institutes

        13.8. Market Value Forecast, by Country, 2017-2031

            13.8.1. U.S.

            13.8.2. Canada

        13.9. Market Attractiveness Analysis

            13.9.1. By Type

            13.9.2. By Drug Molecule

            13.9.3. By Discovery Approach

            13.9.4. By Therapeutic Area

            13.9.5. By Workflow

            13.9.6. By End-user

            13.9.7. By Country

    14. Europe Drug Discovery Outsourcing Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Type, 2017-2031

            14.2.1. Chemistry Services

            14.2.2. Biology Services

        14.3. Market Value Forecast, by Drug Molecule, 2017-2031

            14.3.1. Small Molecules

            14.3.2. Large Molecules

        14.4. Market Value Forecast, by Discovery Approach, 2017-2031

            14.4.1. Empirical Drug Discovery

            14.4.2. Rational Drug Discovery

        14.5. Market Value Forecast, by Therapeutic Area, 2017-2031

            14.5.1. Anti-infective

            14.5.2. Cardiovascular

            14.5.3. Central Nervous System

            14.5.4. Dermatology

            14.5.5. Endocrine

            14.5.6. Gastrointestinal

            14.5.7. Genitourinary System

            14.5.8. Immunomodulation

            14.5.9. Oncology

            14.5.10. Ophthalmology

            14.5.11. Respiratory System

            14.5.12. Others

        14.6. Market Value Forecast, by Workflow, 2017-2031

            14.6.1. Target Identification and Screening

            14.6.2. Lead Identification and Candidate Optimization

            14.6.3. Development of Disease Models

            14.6.4. Pre-formulation Studies

            14.6.5. Entire Clinical Trials

            14.6.6. Others

        14.7. Market Value Forecast, by End-user, 2017-2031

            14.7.1. Pharmaceutical Companies

            14.7.2. Biotechnology Companies

            14.7.3. Academic Institutes

        14.8. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.8.1. Germany

            14.8.2. U.K.

            14.8.3. France

            14.8.4. Italy

            14.8.5. Spain

            14.8.6. Rest of Europe

        14.9. Market Attractiveness Analysis

            14.9.1. By Type

            14.9.2. By Drug Molecule

            14.9.3. By Discovery Approach

            14.9.4. By Therapeutic Area

            14.9.5. By Workflow

            14.9.6. By End-user

            14.9.7. By Country/Sub-region

    15. Asia Pacific Drug Discovery Outsourcing Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Type, 2017-2031

            15.2.1. Chemistry Services

            15.2.2. Biology Services

        15.3. Market Value Forecast, by Drug Molecule, 2017-2031

            15.3.1. Small Molecules

            15.3.2. Large Molecules

        15.4. Market Value Forecast, by Discovery Approach, 2017-2031

            15.4.1. Empirical Drug Discovery

            15.4.2. Rational Drug Discovery

        15.5. Market Value Forecast, by Therapeutic Area, 2017-2031

            15.5.1. Anti-infective

            15.5.2. Cardiovascular

            15.5.3. Central Nervous System

            15.5.4. Dermatology

            15.5.5. Endocrine

            15.5.6. Gastrointestinal

            15.5.7. Genitourinary System

            15.5.8. Immunomodulation

            15.5.9. Oncology

            15.5.10. Ophthalmology

            15.5.11. Respiratory System

            15.5.12. Others

        15.6. Market Value Forecast, by Workflow, 2017-2031

            15.6.1. Target Identification and Screening

            15.6.2. Lead Identification and Candidate Optimization

            15.6.3. Development of Disease Models

            15.6.4. Pre-formulation Studies

            15.6.5. Entire Clinical Trials

            15.6.6. Others

        15.7. Market Value Forecast, by End-user, 2017-2031

            15.7.1. Pharmaceutical Companies

            15.7.2. Biotechnology Companies

            15.7.3. Academic Institutes

        15.8. Market Value Forecast, by Country/Sub-region, 2017-2031

            15.8.1. China

            15.8.2. Japan

            15.8.3. India

            15.8.4. Australia & New Zealand

            15.8.5. Rest of Asia Pacific

        15.9. Market Attractiveness Analysis

            15.9.1. By Type

            15.9.2. By Drug Molecule

            15.9.3. By Discovery Approach

            15.9.4. By Therapeutic Area

            15.9.5. By Workflow

            15.9.6. By End-user

            15.9.7. By Country/Sub-region

    16. Latin America Drug Discovery Outsourcing Market Analysis and Forecast

        16.1. Introduction

            16.1.1. Key Findings

        16.2. Market Value Forecast, by Type, 2017-2031

            16.2.1. Chemistry Services

            16.2.2. Biology Services

        16.3. Market Value Forecast, by Drug Molecule, 2017-2031

            16.3.1. Small Molecules

            16.3.2. Large Molecules

        16.4. Market Value Forecast, by Discovery Approach, 2017-2031

            16.4.1. Empirical Drug Discovery

            16.4.2. Rational Drug Discovery

        16.5. Market Value Forecast, by Therapeutic Area, 2017-2031

            16.5.1. Anti-infective

            16.5.2. Cardiovascular

            16.5.3. Central Nervous System

            16.5.4. Dermatology

            16.5.5. Endocrine

            16.5.6. Gastrointestinal

            16.5.7. Genitourinary System

            16.5.8. Immunomodulation

            16.5.9. Oncology

            16.5.10. Ophthalmology

            16.5.11. Respiratory System

            16.5.12. Others

        16.6. Market Value Forecast, by Workflow, 2017-2031

            16.6.1. Target Identification and Screening

            16.6.2. Lead Identification and Candidate Optimization

            16.6.3. Development of Disease Models

            16.6.4. Pre-formulation Studies

            16.6.5. Entire Clinical Trials

            16.6.6. Others

        16.7. Market Value Forecast, by End-user, 2017-2031

            16.7.1. Pharmaceutical Companies

            16.7.2. Biotechnology Companies

            16.7.3. Academic Institutes

        16.8. Market Value Forecast, by Country/Sub-region, 2017-2031

            16.8.1. Brazil

            16.8.2. Mexico

            16.8.3. Rest of Latin America

        16.9. Market Attractiveness Analysis

            16.9.1. By Type

            16.9.2. By Drug Molecule

            16.9.3. By Discovery Approach

            16.9.4. By Therapeutic Area

            16.9.5. By Workflow

            16.9.6. By End-user

            16.9.7. By Country/Sub-region

    17. Middle East & Africa Drug Discovery Outsourcing Market Analysis and Forecast

        17.1. Introduction

            17.1.1. Key Findings

        17.2. Market Value Forecast, by Type, 2017-2031

            17.2.1. Chemistry Services

            17.2.2. Biology Services

        17.3. Market Value Forecast, by Drug Molecule, 2017-2031

            17.3.1. Small Molecules

            17.3.2. Large Molecules

        17.4. Market Value Forecast, by Discovery Approach, 2017-2031

            17.4.1. Empirical Drug Discovery

            17.4.2. Rational Drug Discovery

        17.5. Market Value Forecast, by Therapeutic Area, 2017-2031

            17.5.1. Anti-infective

            17.5.2. Cardiovascular

            17.5.3. Central Nervous System

            17.5.4. Dermatology

            17.5.5. Endocrine

            17.5.6. Gastrointestinal

            17.5.7. Genitourinary System

            17.5.8. Immunomodulation

            17.5.9. Oncology

            17.5.10. Ophthalmology

            17.5.11. Respiratory System

            17.5.12. Others

        17.6. Market Value Forecast, by Workflow, 2017-2031

            17.6.1. Target Identification and Screening

            17.6.2. Lead Identification and Candidate Optimization

            17.6.3. Development of Disease Models

            17.6.4. Pre-formulation Studies

            17.6.5. Entire Clinical Trials

            17.6.6. Others

        17.7. Market Value Forecast, by End-user, 2017-2031

            17.7.1. Pharmaceutical Companies

            17.7.2. Biotechnology Companies

            17.7.3. Academic Institutes

        17.8. Market Value Forecast, by Country/Sub-region, 2017-2031

            17.8.1. GCC Countries

            17.8.2. South Africa

            17.8.3. Rest of MEA

        17.9. Market Attractiveness Analysis

            17.9.1. By Type

            17.9.2. By Drug Molecule

            17.9.3. By Discovery Approach

            17.9.4. By Therapeutic Area

            17.9.5. By Workflow

            17.9.6. By End-user

            17.9.7. By Country/Sub-region

    18. Competition Landscape

        18.1. Market Player - Competitive Matrix (by tier and size of companies)

        18.2. Market Share Analysis, by Company (2022)

        18.3. Company Profiles

            18.3.1. Charles River Laboratories International, Inc.

                18.3.1.1. Company Overview

                18.3.1.2. Product Portfolio

                18.3.1.3. SWOT Analysis

                18.3.1.4. Financial Overview

                18.3.1.5. Strategic Overview

            18.3.2. WuXi AppTec Co., Ltd.

                18.3.2.1. Company Overview

                18.3.2.2. Product Portfolio

                18.3.2.3. SWOT Analysis

                18.3.2.4. Financial Overview

                18.3.2.5. Strategic Overview

            18.3.3. Albany Molecular Research Inc.

                18.3.3.1. Company Overview

                18.3.3.2. Product Portfolio

                18.3.3.3. SWOT Analysis

                18.3.3.4. Financial Overview

                18.3.3.5. Strategic Overview

            18.3.4. GVK Biosciences Private Limited

                18.3.4.1. Company Overview

                18.3.4.2. Product Portfolio

                18.3.4.3. SWOT Analysis

                18.3.4.4. Financial Overview

                18.3.4.5. Strategic Overview

            18.3.5. Sygnature Discovery

                18.3.5.1. Company Overview

                18.3.5.2. Product Portfolio

                18.3.5.3. SWOT Analysis

                18.3.5.4. Financial Overview

                18.3.5.5. Strategic Overview

            18.3.6. Pharmaron Beijing Co., Ltd.

                18.3.6.1. Company Overview

                18.3.6.2. Product Portfolio

                18.3.6.3. SWOT Analysis

                18.3.6.4. Financial Overview

                18.3.6.5. Strategic Overview

            18.3.7. Domainex Ltd.

                18.3.7.1. Company Overview

                18.3.7.2. Product Portfolio

                18.3.7.3. SWOT Analysis

                18.3.7.4. Financial Overview

                18.3.7.5. Strategic Overview

            18.3.8. Thermo Fisher Scientific, Inc.

                18.3.8.1. Company Overview

                18.3.8.2. Product Portfolio

                18.3.8.3. SWOT Analysis

                18.3.8.4. Financial Overview

                18.3.8.5. Strategic Overview

            18.3.9. Jubilant Biosys Ltd.

                18.3.9.1. Company Overview

                18.3.9.2. Product Portfolio

                18.3.9.3. SWOT Analysis

                18.3.9.4. Financial Overview

                18.3.9.5. Strategic Overview

            18.3.10. Evotec SE

                18.3.10.1. Company Overview

                18.3.10.2. Product Portfolio

                18.3.10.3. SWOT Analysis

                18.3.10.4. Financial Overview

                18.3.10.5. Strategic Overview

            18.3.11. Eurofins Discovery

                18.3.11.1. Company Overview

                18.3.11.2. Product Portfolio

                18.3.11.3. SWOT Analysis

                18.3.11.4. Financial Overview

                18.3.11.5. Strategic Overview

            18.3.12. GenScript Biotech Corporation

                18.3.12.1. Company Overview

                18.3.12.2. Product Portfolio

                18.3.12.3. SWOT Analysis

                18.3.12.4. Financial Overview

                18.3.12.5. Strategic Overview

    List of Tables

    Table 01: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031

    Table 02: Global Drug Discovery Outsourcing Market Value (`) Forecast, by Drug Molecule, 2017-2031

    Table 03: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031

    Table 04: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031

    Table 05: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031

    Table 06: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031

    Table 07: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Region, 2017-2031

    Table 08: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031

    Table 09: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031

    Table 10: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031

    Table 11: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031

    Table 12: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031

    Table 13: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031

    Table 14: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country, 2017-2031

    Table 15: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031

    Table 16: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031

    Table 17: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031

    Table 18: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031

    Table 19: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031

    Table 20: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031

    Table 21: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031

    Table 23: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031

    Table 24: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031

    Table 25: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031

    Table 26: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031

    Table 27: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031

    Table 28: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

    Table 29: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031

    Table 30: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031

    Table 31: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031

    Table 32: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031

    Table 33: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031

    Table 34: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031

    Table 35: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

    Table 36: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031

    Table 37: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031

    Table 38: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031

    Table 39: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031

    Table 40: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031

    Table 41: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031

    Table 42: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

    List of Figures

    Figure 01: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031

    Figure 02: Global Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031

    Figure 03: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031

    Figure 04: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Target Identification and Screening, 2017-2031

    Figure 05: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Lead Identification and Candidate Optimization, 2017-2031

    Figure 06: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Development of Disease Models, 2017-2031

    Figure 07: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Pre-formulation Studies, 2017-2031

    Figure 08: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Entire Clinical Trials, 2017-2031

    Figure 09: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Others, 2017-2031

    Figure 10: Global Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031

    Figure 11: Global Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031

    Figure 12: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Small Molecules, 2017-2031

    Figure 13: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Large Molecules, 2017-2031

    Figure 14: Global Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031

    Figure 15: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Empirical Drug Discovery, 2017-2031

    Figure 16: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Rational Drug Discovery, 2017-2031

    Figure 17: Global Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 18: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Anti-infective, 2017-2031

    Figure 19: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Cardiovascular, 2017-2031

    Figure 20: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Central Nervous System, 2017-2031

    Figure 21: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Dermatology, 2017-2031

    Figure 22: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Endocrine, 2017-2031

    Figure 23: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Gastrointestinal, 2017-2031

    Figure 24: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Genitourinary System, 2017-2031

    Figure 25: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Immunomodulation, 2017-2031

    Figure 26: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Oncology, 2017-2031

    Figure 27: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Ophthalmology, 2017-2031

    Figure 28: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Respiratory System, 2017-2031

    Figure 29: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Others, 2017-2031

    Figure 30: Global Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031

    Figure 31: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031

    Figure 32: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Chemistry Services, 2017-2031

    Figure 33: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Biology Services, 2017-2031

    Figure 34: Global Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 35: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031

    Figure 36: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Pharmaceutical Companies, 2017-2031

    Figure 37: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Biotechnology Companies, 2017-2031

    Figure 38: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Academic Institutes, 2017-2031

    Figure 39: Global Drug Discovery Outsourcing Market Value Share Analysis, by Region, 2022 and 2031

    Figure 40: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by Region, 2022-2031

    Figure 41: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031

    Figure 42: North America Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031

    Figure 43: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031

    Figure 44: North America Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031

    Figure 45: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031

    Figure 46: North America Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031

    Figure 47: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031

    Figure 48: North America Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 49: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031

    Figure 50: North America Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031

    Figure 51: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031

    Figure 52: North America Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 53: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031

    Figure 54: North America Drug Discovery Outsourcing Market Value Share Analysis, by Country, 2022 and 2031

    Figure 55: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Country, 2022-2031

    Figure 56: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031

    Figure 57: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031

    Figure 58: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031

    Figure 59: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031

    Figure 60: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031

    Figure 61: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031

    Figure 62: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031

    Figure 63: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 64: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031

    Figure 65: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031

    Figure 66: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031

    Figure 67: Europe Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 68: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031

    Figure 69: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 70: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031

    Figure 71: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031

    Figure 72: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031

    Figure 73: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031

    Figure 74: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031

    Figure 75: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031

    Figure 76: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031

    Figure 77: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031

    Figure 78: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 79: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031

    Figure 80: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031

    Figure 81: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031

    Figure 82: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 83: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031

    Figure 84: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 85: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031

    Figure 86: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031

    Figure 87: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031

    Figure 88: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031

    Figure 89: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031

    Figure 90: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031

    Figure 91: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031

    Figure 92: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031

    Figure 93: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 94: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031

    Figure 95: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031

    Figure 96: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031

    Figure 97: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 98: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031

    Figure 99: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 100: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031

    Figure 101: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031

    Figure 102: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031

    Figure 103: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031

    Figure 104: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031

    Figure 105: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031

    Figure 106: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031

    Figure 107: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031

    Figure 108: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 109: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031

    Figure 110: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031

    Figure 111: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031

    Figure 112: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 113: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031

    Figure 114: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 115: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031

Copyright © Transparency Market Research, Inc. All Rights reserved